- Adjusted EBITDA loss was approximately $3 million, slightly worse than the $2.9 million loss in Q1.
- Cash and equivalents totaled approximately $777.5 million at quarter end, with expected year-end cash around $770 million after planned expenditures.
- GAAP operating expenses rose to $54.1 million from $48.1 million in Q1, including a $9.9 million noncash impairment charge.
- Non-GAAP gross margin was 44.2%, GAAP gross margin was 42.1%, both improved year-over-year and sequentially due to operational efficiencies and one-time adjustments.
- Non-GAAP income was approximately $2.1 million or $0.07 per share on 30.7 million diluted shares.
- Non-GAAP operating expenses increased to $43.9 million from $37.4 million in Q1, driven by R&D and sales/marketing investments.
- Revenue in Q2 2025 was $81.8 million, up from $73.5 million in Q1 2025, with core business revenue at $81.7 million excluding COVID-19 testing.
- The company repurchased 130,000 shares for $2.2 million in Q2, with $139.6 million remaining in the repurchase program.
Related items and other data are not available for this feed item.